PMID- 36678531
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230202
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 16
IP  - 1
DP  - 2022 Dec 27
TI  - Combinatory Effect and Modes of Action of Chrysin and Bone Marrow-Derived 
      Mesenchymal Stem Cells on Streptozotocin/Nicotinamide-Induced Diabetic Rats.
LID - 10.3390/ph16010034 [doi]
LID - 34
AB  - The purpose of this study was to see how chrysin and/or bone marrow-derived 
      mesenchymal stem cells (BM-MSCs) affected streptozotocin (STZ)/nicotinamide 
      (NA)-induced diabetic rats as an animal model of type 2 diabetes mellitus (T2DM). 
      Male Wistar rats were given a single intraperitoneal (i.p.) injection of 60 mg 
      STZ/kg bodyweight (bw) 15 min after an i.p. injection of NA (120 mg/kg bw) to 
      induce T2DM. The diabetic rats were given chrysin orally at a dose of 100 mg/kg 
      bw every other day, BM-MSCs intravenously at a dose of 1 x 10(6) cells/rat/week, 
      and their combination for 30 days after diabetes induction. The rats in the 
      diabetic group displayed impaired oral glucose tolerance and a decrease in liver 
      glycogen content and in serum insulin, C-peptide, and IL-13 levels. They also had 
      significantly upregulated activities in terms of liver glucose-6-phosphatase and 
      glycogen phosphorylase and elevated levels of serum free fatty acids, IL-1beta, and 
      TNF-alpha. In addition, the diabetic rats exhibited a significant elevation in the 
      adipose tissue resistin protein expression level and a significant decrease in 
      the expression of adiponectin, insulin receptor-beta subunit, insulin receptor 
      substrate-1, and insulin receptor substrate-2, which were associated with a 
      decrease in the size of the pancreatic islets and in the number of beta-cells and 
      insulin granules in the islets. The treatment of diabetic rats with chrysin 
      and/or BM-MSCs significantly improved the previously deteriorated alterations, 
      with chrysin combined with BM-MSCs being the most effective. Based on these 
      findings, it can be concluded that combining chrysin with BM-MSCs produced 
      greater additive therapeutic value than using them separately in NA/STZ-induced 
      T2DM rats.
FAU - Sayed, Hesham M
AU  - Sayed HM
AUID- ORCID: 0000-0002-8292-9272
AD  - Physiology Division, Department of Zoology, Faculty of Science, Beni-Suef 
      University, Beni Suef 62521, Egypt.
FAU - Awaad, Ashraf S
AU  - Awaad AS
AD  - Department of Anatomy and Embryology, Faculty of Veterinary Medicine, Beni-Suef 
      University, Beni Suef 62521, Egypt.
FAU - Abdel Rahman, Fatma El-Zahraa S
AU  - Abdel Rahman FES
AD  - Department of Basic Sciences, Faculty of Oral and Dental Medicine, Nahda 
      University, Beni Suef 62764, Egypt.
FAU - Al-Dossari, M
AU  - Al-Dossari M
AUID- ORCID: 0000-0003-0642-5117
AD  - Department of Physics, Faculty of Science, King Khalid University, Abha 62529, 
      Saudi Arabia.
FAU - Abd El-Gawaad, N S
AU  - Abd El-Gawaad NS
AUID- ORCID: 0000-0001-5606-3906
AD  - Department of Physics, Faculty of Science, King Khalid University, Abha 62529, 
      Saudi Arabia.
FAU - Ahmed, Osama M
AU  - Ahmed OM
AUID- ORCID: 0000-0003-3781-9709
AD  - Physiology Division, Department of Zoology, Faculty of Science, Beni-Suef 
      University, Beni Suef 62521, Egypt.
LA  - eng
GR  - KKU/RCAMS/008-22/This work was supported by the King Khalid University through a 
      grant KKU/RCAMS/008-22 under the Research Center for Advanced Materials Science 
      (RCAMS) at King Khalid University, Saudi Arabia./
PT  - Journal Article
DEP - 20221227
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC9863970
OTO - NOTNLM
OT  - NA/STZ-induced diabetes mellitus
OT  - chrysin
OT  - mesenchymal stem cells
COIS- The authors declared there no conflict of interest.
EDAT- 2023/01/22 06:00
MHDA- 2023/01/22 06:01
PMCR- 2022/12/27
CRDT- 2023/01/21 01:48
PHST- 2022/10/11 00:00 [received]
PHST- 2022/11/25 00:00 [revised]
PHST- 2022/12/18 00:00 [accepted]
PHST- 2023/01/21 01:48 [entrez]
PHST- 2023/01/22 06:00 [pubmed]
PHST- 2023/01/22 06:01 [medline]
PHST- 2022/12/27 00:00 [pmc-release]
AID - ph16010034 [pii]
AID - pharmaceuticals-16-00034 [pii]
AID - 10.3390/ph16010034 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2022 Dec 27;16(1):34. doi: 10.3390/ph16010034.